Found: 9
Select item for more details and to access through your institution.
Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
- Published in:
- NPJ Parkinson's Disease, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41531-021-00246-y
- By:
- Publication type:
- Article
Whole body vibration exercise in the management of cancer therapy-related morbidities: A systematic review.
- Published in:
- Drug Discoveries & Therapeutics, 2018, v. 12, n. 4, p. 239, doi. 10.5582/ddt.2018.01039
- By:
- Publication type:
- Article
Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project.
- Published in:
- Brain Sciences (2076-3425), 2021, v. 11, n. 8, p. 1027, doi. 10.3390/brainsci11081027
- By:
- Publication type:
- Article
Chenopodium ambrosioides associated with whole body vibration exercises alters the feed intake in Wistar rats.
- Published in:
- Bioscience Reports, 2017, v. 37, n. 4, p. 1, doi. 10.1042/BSR20170846
- By:
- Publication type:
- Article
Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
- Published in:
- Movement Disorders, 2021, v. 36, n. 11, p. 2615, doi. 10.1002/mds.28703
- By:
- Publication type:
- Article
MNCD: A New Tool for Classifying Parkinson's Disease in Daily Clinical Practice.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 1, p. 55, doi. 10.3390/diagnostics12010055
- By:
- Publication type:
- Article
Dyskinesia and Pain in Advanced Parkinson's Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study.
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 2, p. 437, doi. 10.1007/s40120-024-00583-z
- By:
- Publication type:
- Article
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
- Published in:
- Neurology & Therapy, 2023, v. 12, n. 6, p. 1937, doi. 10.1007/s40120-023-00533-1
- By:
- Publication type:
- Article